🚨 Oncology Breakthroughs You Can’t Miss! 🚨
From pediatric approvals in Australia and next-gen immunotherapies to global clinical milestones, this week’s Oncology Updates delivers the latest advances shaping cancer care worldwide.
🔬 Highlights from this week’s edition:
🇦🇺 IFINWIL approved in Australia for high-risk neuroblastoma—offering new options for children where survival rates in high-risk cases remain around fifty percent
👁️ IDEAYA Biosciences moves its uveal melanoma therapy, darovasertib, into Phase 3, prioritizing eye preservation with FDA Breakthrough and Orphan Drug designations
🧪 Aulos Bioscience launches a Phase 2 trial for AI-designed IL-2 modulator AU-007 plus nivolumab in melanoma, following promising early data
💉 Henlius initiates a Phase 2 study in China for HLX22 plus T-DXd, targeting HER2-low, hormone receptor-positive breast cancer
🇨🇦 Health Canada expands Jemperli (dostarlimab) use with chemotherapy for MMRp/MSS endometrial cancer after RUBY Phase 3 data shows a thirty-one percent reduction in risk of death
🇮🇳 AstraZeneca withdraws olaparib from the Indian market for metastatic prostate cancer for commercial reasons—note, the drug was never launched post-approval
🧬 Cardiff Oncology completes enrollment in a Phase 2 trial of onvansertib plus standard-of-care for first-line RAS-mutant metastatic colorectal cancer, with results expected in the first half of 2025
⚖️ Endevica Bio starts a 100-patient Phase 2 trial of TCMCB07 targeting cancer cachexia in colorectal cancer—a field with no FDA-approved therapies
🧫 Accent Therapeutics doses the first patient in a Phase 1/2 trial of ATX-295 targeting chromosomal instability and secures Fast Track designation for both ATX-295 (ovarian cancer) and ATX-559 (colorectal cancer)
🦴 SynOx Therapeutics receives FDA Fast Track status for emactuzumab in tenosynovial giant cell tumor patients who are ineligible for surgery, with Phase 3 TANGENT underway
🔬 Pheast Therapeutics begins its Phase 1 trial of macrophage checkpoint inhibitor PHST001 for solid tumors, enrolling up to 80 patients
📢 Stay Ahead in Oncology Research!
✅ Like, share, and subscribe for weekly updates on oncology, cancer immunotherapy, and clinical breakthroughs
#OncologyUpdates #CancerResearch #TargetedTherapies #Neuroblastoma #Melanoma #BreastCancer #EndometrialCancer #ColorectalCancer #ProstateCancer #TGCT #ClinicalTrials #Immunotherapy #LucidQuest #HealthcareInnovation